The Treatment-Naive Microbiome in New-Onset Crohn’s DiseaseDirk Gevers, Ramnik J. Xavier, Lee A. Denson et al.|Cell Host & Microbe|2014Cited by 3.3k
Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signatureYael Haberman, Lee A. Denson, Timothy L. Tickle et al.|Journal of Clinical Investigation|2015Cited by 31
41 Serious Infections and Associated Risk Factors in Patients Receiving Infliximab and Immunotherapies for Children With Inflammatory Bowel Disease: Develop Registry DataRobert N. Baldassano, Harland S. Winter, Richard B. Colletti et al.|Gastroenterology|2013Cited by 8
833 Malignancies in Children Receiving Infliximab and Other Inflammatory Bowel Disease Therapies: An Inflammatory Bowel Disease Multicenter, Prospective, Long-Term Registry of Pediatric Patients (Develop) Registry DataRichard B. Colletti, Gigi Veereman, Salvatore Cucchiara et al.|Gastroenterology|2013Cited by 7
W1181 Long-Term Efficacy and Safety of Maintenance Infliximab for the Treatment of Moderate-to-Severe Pediatric Crohn's Disease: Results from the Reach StudyJeffrey S. Hyams, Robert N. Baldassano, Marion Blank et al.|Gastroenterology|2009Cited by 2